President and Chief Executive Officer of Sangamo BioSciences to Present at GTCbio`s 4th International Stem Cell Research and Therapeutics, Apr 17-18, 2008 in Boston, MA
Released on: March 19, 2008, 4:50 pm
Press Release Author: Gtobio
Industry:
Press Release Summary: Edward Lanphier, President & Chief Executive Officer at Sangamo BioSciences, which published a new study last October indicating that its technology could be used to modify the genomes in stem cells, create stem cell lines that mimic disease, and modify stem cells to treat diseases, will present at the 4th International Stem Cell Research & Therapeutics, Apr 17-18, 2008 in Boston, MA.
Press Release Body: Edward Lanphier, President & Chief Executive Officer at Sangamo BioSciences, which published a new study last October indicating that its technology could be used to modify the genomes in stem cells, create stem cell lines that mimic disease, and modify stem cells to treat diseases, will present at the 4th International Stem Cell Research & Therapeutics, Apr 17-18, 2008 in Boston, MA.
Dr. Lanphier will discuss stem cell mobilization and directed differentiation and the role of zinc finger proteins (ZFPs) in stem cell research and therapies. ZFPs are the dominant class of naturally occurring DNA-binding motifs found in nature. Efficient and highly precise gene regulation or modification can be achieved by engineering ZFPs to bind to and recognize a specific DNA sequence. Using this powerful platform, ZFPs have been designed that promote the mobilization of endogenous human stem cells providing strategies for cell regeneration and cell repair. Use of zinc finger nucleases (ZFN) for precision \"genome editing" has enabled specific gene modification or targeted gene addition for directed differentiation in human stem cells. This workshop addresses the role of engineered zinc finger proteins in stem cell mobilization and in modification of human stem cells for correction of genetic disease..
The conference also features presentations from other leading organizations such as FDA, Genzyme, Geron, Joint Committee on Health Care Financing (by Senator Richard Moore), Merck, MIT, Novartis, Pfizer, Sanofi Aventis, Stemagen, UCSB, University of Van Amsterdam, Whitehead Institute, and many more. The full agenda is available online at www.gtcbio.com.
GTCbio's 4th Stem Cell Research & Therapeutics will take place on April 17-18, 2008 in Boston, MA and will cover Stem Cell Biology, Adult Stem Cells, Embryonic Stem Cells, Differentiation of Stem Cells, Epigenomics & Reprogramming of Stem Cells, Regenerative Medicine & Therapeutics, Stem Cell Imaging, Regulatory Aspects & Funding Opportunities, Cancer Stem Cells, and Stem Cell Applications in Drug Discovery.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/userAgenda.aspx?id=120
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
2012
